RS50692B - Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera - Google Patents
Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kanceraInfo
- Publication number
- RS50692B RS50692B RSP-2008/0567A RSP20080567A RS50692B RS 50692 B RS50692 B RS 50692B RS P20080567 A RSP20080567 A RS P20080567A RS 50692 B RS50692 B RS 50692B
- Authority
- RS
- Serbia
- Prior art keywords
- combination
- cancer
- drugs
- treatment
- fluorouracil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Primena, naznačena time što se ET-743 primenjuje u kombinaciji sa terapeutski efikasnom količinom proleka 5-fluorouracila, izabranog od kapecitabina ili jedinjenja formule:• gde su svako R1 , R2 i R3 nezavisno vodonik, ili radikal koji se lako može hidrolizovati pod fiziološkim uslovima, uz uslov daje, najmanje jedan od R1 , R2 ili R3 radikal koji se može lako hidrolizovati pod fiziološkim uslovima;• kao i hidrata ili solvata jedinjenja opšte formule (I); ili• jedinjenja formule (II)• gde je R1 zasićeni pravolančani ili granati ugljovodonični radikal u kome je broj ugljenikovih atoma u najdužem pravom lancu ovog ugljovodoničnog radikala u opsegu od tri do sedam, ili je radikal formule—(CH2)n—y gde je Y cikloheksil radikal, C1-C4 alkoksi radikal ili fenil radikal i gde, kada je Y cikloheksil radikal, tada je n ceo broj od 0 do 4, i kada je Y jednak C1-C4 alkoksi radikal ili fenil radikal, tada je n ceo broj od 2 do 4, i R2 je atom vodonika ili radikal koji se lako može hidrolizovati pod fiziološkim uslovima ili njegovi hidrati ili solvat, za pripremu leka za lečenje ljudskog tela sa kancerom. Prijava sadrži još 19 patentnih zahteva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51969003P | 2003-11-13 | 2003-11-13 | |
PCT/GB2004/050026 WO2005049031A1 (en) | 2003-11-13 | 2004-11-15 | Combination |
Publications (1)
Publication Number | Publication Date |
---|---|
RS50692B true RS50692B (sr) | 2010-06-30 |
Family
ID=34619369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2008/0567A RS50692B (sr) | 2003-11-13 | 2004-11-15 | Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera |
Country Status (15)
Country | Link |
---|---|
US (1) | US7622458B2 (sr) |
EP (1) | EP1689404B9 (sr) |
JP (1) | JP2007511499A (sr) |
AT (1) | ATE406897T1 (sr) |
CA (1) | CA2544320A1 (sr) |
CY (1) | CY1108629T1 (sr) |
DE (1) | DE602004016376D1 (sr) |
DK (1) | DK1689404T3 (sr) |
ES (1) | ES2314470T3 (sr) |
HR (1) | HRP20080598T3 (sr) |
PL (1) | PL1689404T3 (sr) |
PT (1) | PT1689404E (sr) |
RS (1) | RS50692B (sr) |
SI (1) | SI1689404T1 (sr) |
WO (1) | WO2005049031A1 (sr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
NZ525730A (en) * | 2000-11-06 | 2004-12-24 | Pharma Mar S | Compositions for antitumour treatments containing Ecteinascidin 743 |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
PT1689404E (pt) | 2003-11-13 | 2008-12-15 | Pharma Mar Sau | Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro |
AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
CN101119750B (zh) * | 2004-10-26 | 2013-03-06 | 法马马私人股份有限公司 | 抗癌治疗 |
PL1658848T3 (pl) * | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Preparaty zawierające ekteinascydynę i disacharyd |
US20080292729A1 (en) * | 2005-07-21 | 2008-11-27 | Nuvo Research Inc. | Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
US20100267732A1 (en) * | 2007-10-19 | 2010-10-21 | Pharma Mar, S.A. | Prognostic Molecular Markers for ET-743 Treatment |
EP2786755A3 (en) * | 2010-11-12 | 2014-10-29 | Pharma Mar S.A. | Combination therapy with an antitumor alkaloid |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
JP7303205B2 (ja) * | 2018-02-12 | 2023-07-04 | アレイ・バイオファーマ・インコーポレーテッド | 胆道癌を処置するための方法および併用療法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US20040059112A1 (en) | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
CA2327468C (en) | 1998-04-06 | 2008-05-06 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic ecteinascidins |
US6316214B1 (en) | 1998-05-11 | 2001-11-13 | The Board Of Trustees Of The University Of Illinois | ETM-775 metabolite of ecteinascidin 743 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
CZ298259B6 (cs) * | 2000-02-28 | 2007-08-08 | Aventis Pharma S. A. | Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin |
PT1280809E (pt) | 2000-04-12 | 2005-11-30 | Pharma Mar Sa | Derivados antitumorais de ecteinascidina |
EP1356097A2 (en) | 2000-08-11 | 2003-10-29 | City of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
NZ525730A (en) | 2000-11-06 | 2004-12-24 | Pharma Mar S | Compositions for antitumour treatments containing Ecteinascidin 743 |
EP1360337A1 (en) | 2001-02-09 | 2003-11-12 | The Regents Of The University Of California | Ecteinascidin family compounds: compositions and methods |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
BR0213424A (pt) | 2001-10-19 | 2004-12-14 | Pharma Mar Sa | Uso aperfeiçoado de composto antitumoral na terapia contra câncer |
US20040019027A1 (en) | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
GB0312407D0 (en) | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
PT1689404E (pt) | 2003-11-13 | 2008-12-15 | Pharma Mar Sau | Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro |
AU2004291037A1 (en) | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
WO2006035244A2 (en) | 2004-09-29 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
CN101119750B (zh) | 2004-10-26 | 2013-03-06 | 法马马私人股份有限公司 | 抗癌治疗 |
PL1658848T3 (pl) | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Preparaty zawierające ekteinascydynę i disacharyd |
-
2004
- 2004-11-15 PT PT04798717T patent/PT1689404E/pt unknown
- 2004-11-15 SI SI200430928T patent/SI1689404T1/sl unknown
- 2004-11-15 ES ES04798717T patent/ES2314470T3/es active Active
- 2004-11-15 AT AT04798717T patent/ATE406897T1/de active
- 2004-11-15 EP EP04798717A patent/EP1689404B9/en active Active
- 2004-11-15 US US10/579,160 patent/US7622458B2/en not_active Expired - Fee Related
- 2004-11-15 PL PL04798717T patent/PL1689404T3/pl unknown
- 2004-11-15 DE DE602004016376T patent/DE602004016376D1/de active Active
- 2004-11-15 DK DK04798717T patent/DK1689404T3/da active
- 2004-11-15 JP JP2006538970A patent/JP2007511499A/ja active Pending
- 2004-11-15 WO PCT/GB2004/050026 patent/WO2005049031A1/en active Application Filing
- 2004-11-15 CA CA002544320A patent/CA2544320A1/en not_active Abandoned
- 2004-11-15 RS RSP-2008/0567A patent/RS50692B/sr unknown
-
2008
- 2008-12-02 HR HR20080598T patent/HRP20080598T3/xx unknown
- 2008-12-02 CY CY20081101393T patent/CY1108629T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2314470T3 (es) | 2009-03-16 |
EP1689404A1 (en) | 2006-08-16 |
JP2007511499A (ja) | 2007-05-10 |
CY1108629T1 (el) | 2014-04-09 |
PT1689404E (pt) | 2008-12-15 |
CA2544320A1 (en) | 2005-06-02 |
EP1689404B1 (en) | 2008-09-03 |
ATE406897T1 (de) | 2008-09-15 |
DE602004016376D1 (de) | 2008-10-16 |
DK1689404T3 (da) | 2009-01-26 |
EP1689404B9 (en) | 2009-04-22 |
SI1689404T1 (sl) | 2009-02-28 |
US7622458B2 (en) | 2009-11-24 |
US20070190164A1 (en) | 2007-08-16 |
WO2005049031A1 (en) | 2005-06-02 |
HRP20080598T3 (en) | 2009-01-31 |
PL1689404T3 (pl) | 2009-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20080598T3 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
NZ544472A (en) | Compounds and therapeutical use thereof | |
PL350313A1 (en) | Apomorphine and sildenafil composition | |
WO2006113802A3 (en) | Device for administering electrode stimulation of back and abdominal muscles | |
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
NO20072543L (no) | Anti-cancer-behandling | |
AU1249902A (en) | Effective antitumour treatments | |
MY164077A (en) | Compositions and uses of et743 for treating cancer | |
BR0313117A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
WO2000057867A3 (en) | Improved cancer treatment with temozolomide | |
AU2001236529A1 (en) | Combination therapy for cancer | |
IL159770A0 (en) | Calcium salts with cytotoxic activity | |
UA11290U (uk) | Спосіб профілактики антрациклінового ушкодження серця |